So a few things - dosing is probably at 50 mg twice daily. On GoodRx, CVS has 60 x 50 mg for $67.
There are a long list of serious reactions such as metabolic acidosis, electrolyte imbalance, anaphylaxis, erythema multiforme, Stevens-Johnson Syndrome/Toxic epidermal necrolysis, hepatic necrosis, agranulocytosis, hemolytic anemia, myelosuppression, seizures, paralysis. Then on to the common reactions, fatigue, malaise, anorexia, nausea, vomiting, paresthesia, diarrhea, drowsiness, confusion, hives, photosensitivity and lots more.
It would seem like you’d have to have a pretty good reason to do this, and not something to casually ingest without monitoring with a professional.
Here is what Vera-Health.ai says on the topic:
Methazolamide, a carbonic anhydrase inhibitor (CAI), is being explored for its potential therapeutic effects in Alzheimer’s disease (AD). Carbonic anhydrases are enzymes involved in maintaining pH balance and other physiological processes in the brain. Inhibiting these enzymes may help alleviate some pathological features of AD, such as amyloid beta (Aβ) accumulation, mitochondrial dysfunction, and cerebrovascular issues.
Research indicates that methazolamide, along with other CAIs like acetazolamide, can inhibit Aβ-mediated mitochondrial dysfunction and apoptosis in vascular, glial, and neuronal cells, which are key features of AD pathology 3. Methazolamide has shown the ability to prevent the activation of apoptotic pathways induced by Aβ in brain vascular smooth muscle cells, potentially improving cerebrovascular health and reducing cognitive impairment 1.
In transgenic mouse models of AD and cerebral amyloid angiopathy, methazolamide significantly reduced cerebral amyloidosis, Aβ accumulation, and improved cognitive function 1. This suggests a protective role against neurovascular mitochondrial toxicity, a hallmark of AD and related neurodegenerative conditions 1.
Methazolamide’s potential in AD treatment is further supported by its ability to cross the blood-brain barrier and its established safety profile as an FDA-approved drug for other conditions 1. However, more research is needed to fully understand the mechanisms by which methazolamide exerts its effects and to determine its efficacy and safety in clinical settings for AD patients.
In summary, methazolamide shows promise as a therapeutic agent for Alzheimer’s dementia by targeting mitochondrial dysfunction and Aβ pathology. However, further clinical trials are necessary to establish its role and effectiveness in AD treatment.